Open access · US-GOV
via ClinicalTrials.gov Clinical trial
AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation (AGEING) - a Feasibility Study
Authors not listed
University Hospital Birmingham NHS Foundation Trust · 2017
Abstract
The proportion of elderly patients with end-stage kidney disease undergoing renal replacement therapy (RRT) is steadily increasing. Although kidney transplantation remains the optimal RRT of choice, it is clear that older adults have a differential risk versus benefit profile after kidney transplantation compared to younger adults. No age-adapted immunosuppression for older adults has been shown to improve kidney allograft outcomes but recent sub-analyses of clinical trial data has hinted at improved outcomes for older kidney transplant patients receiving Envarsus versus standard twice-daily tacrolimus formulations. This feasibility study will investigate this effect to see whether a full scale randomised controlled trial is warranted and to provide information regarding study feasibility.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-04 MST
Cite this
APA
Anonymous. (2017). AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation (AGEING) - a Feasibility Study. <em>University Hospital Birmingham NHS Foundation Trust</em>. https://clinicaltrials.gov/study/NCT03005236
Vancouver
Anonymous. AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation (AGEING) - a Feasibility Study. University Hospital Birmingham NHS Foundation Trust. 2017.
BibTeX
@misc{anon2017AGeada,
title = {AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation (AGEING) - a Feasibility Study},
author = {Anonymous},
journal = {University Hospital Birmingham NHS Foundation Trust},
year = {2017},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Indiana University 2010
Open access · US-GOV
Alzheimer's Disease Multiple Intervention Trial
Universität Münster 2026
Open access · US-GOV
The Effect of Standard vs. Shorter Filter Lifespan During Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury - a Feasibility Randomized Controlled Trial
Wake Forest University Health Sciences 2024
Open access · US-GOV
Anticipating Decline and Providing Therapy (ADAPT): Post-ICU Cognitive Screening Pilot and Feasibility Randomized Controlled Trial
Turku University Hospital 2025
Open access · US-GOV
SEDentary Lifestyle, Mortality and Major Adverse Clinical Outcomes in Chronic KIDney Disease. A Prospective Multicenter Follow-up Protocol With a Nested Randomized Controlled Trial of Physical Education Benefits - The SEDKID Study
First Affiliated Hospital of Zhejiang University 2026
Open access · US-GOV
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
Brigham and Women's Hospital 2025
Open access · US-GOV